30 years of rabies vaccination with Rabipur: A summary of clinical data and global experience

Expert Review of Vaccines

Volumn 14, Issue 3, 2015, Pages 351-367

  Giesen, Alexandra ^a   Gniel, Dieter ^a   Malerczyk, Claudius ^a  

^a Novartis Vaccines and Diagnostics GmbH   (Germany)

Author keywords

cell culture vaccine; efficacy; exposure; immunogenicity; intradermal; intramuscular; post exposure prophylaxis; pre exposure prophylaxis; purified chick embryo cell vaccine; rabies; Rabipur; safety; vaccine

Indexed keywords

RABIES IMMUNOGLOBULIN; RABIES VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FIBROBLAST; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; LYSSAVIRUS; MALNUTRITION; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PRIORITY JOURNAL; RABIES; VACCINATION; VIRUS STRAIN; ADVERSE EFFECTS; HEALTH; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; PROCEDURES;

GLOBAL HEALTH; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; POST-EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; VACCINATION;

EID: 84923082469     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1011134     Document Type: Article

References (119)

1. Rabies (Fact sheet No. 99). World Health Organization. Available from: www.who.int/mediacentre/factsheets/fs099/en/[Last accessed 25 March 2014]
2. Fekadu M, Endeshaw T, Alemu W, et al. Possible human-to-human transmission of rabies in Ethiopia. Ethiop Med J 1996;34: 123-7
3. Maier T, Schwarting A, Mauer D, et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis 2010;50:1112-19
4. Noah DL, Drenzek CL, Smith JS, et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998;128:922-30
5. Smith J, Fishbein D, Rupprecht C, Clark K. Unexplained rabies in three immigrants in the United States. A Virologic Investigation. N Engl J Med 1991;324(4):205-11
6. Yousaf MZ, Qasim M, Zia S, et al. Rabies molecular virology, diagnosis, prevention and treatment. Virol J 2012;9:50
7. Rabies. World Health Organization. Available from: www.who.int/rabies/en/[Last accessed 25 March 2014]
8. WHO Expert Consultation on Rabies. Second report. World Health Organization. World Health Organ Tech Rep Ser 2013 (982):1-139; back cover
9. Bourhy H, Dautry-Varsat A, Hotez PJ, Salomon J. Rabies, still neglected after 125 years of vaccination. PLoS Negl Trop Dis 2010;4:e839
10. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second WHO report on neglected tropical diseases. World Health Organization; Geneva: 2013. p. 1-153
11. Rupprecht CE, Shlim DR. Infectious diseases related to travel-rabies. In: Brunette G, Kozarsky PE, Magill J, Shlim D, Whatley A, editors. CDC Health information for international travel: The Yellow Book 2014. Oxford University Press; New York, NY: 2014. p. 270-6
12. Kammer AR, Ertl HC. Rabies vaccines: from the past to the 21st century. Hybrid Hybridomics 2002;21:123-7
13. Javier RS, Kunishita T, Koike F, Tabira T. Semple rabies vaccine: presence of myelin basic protein and proteolipid protein and its activity in experimental allergic encephalomyelitis. J Neurol Sci 1989;93: 221-30
14. World Health Organization expert committee on rabies. Seventh report. World Health Organ Tech Rep Ser 1984;709: 1-104
15. Information Sheet: observed rate of vaccine reactions. Rabies Vaccine. World Health Organization. Available from: www.who.int/vaccine-safety/initiative/tools/Rabies-Vaccine-rates-information-sheet.pdf [Last accessed 25 March 2014]
16. WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans. World Health Organization. Available from: www. who.int/rabies/WHO-Guide-Rabies-Pre- Post-Exposure-Prophylaxis-Humans-2013. pdf [Last accessed 25 March 2014]
17. Fuenzalida E, Palacios R, Borgono JM. Antirabies antibody response in man to vaccine made from infected suckling-mouse brains. Bull World Health Organ 1964;30: 431-6
18. Lavender JF, van Frank RM. Zonal-centrifuged purified duck embryo cell culture rabies vaccine for human vaccination. Appl Microbiol 1971;22: 358-65
19. Fenje P. A rabies vaccine from hamster kidney tissue cultures: preparation and evaluation in animals. Can J Microbiol 1960;6:605-9
20. Kissling RE, Reese DR. Anti-Rabies vaccine of tissue culture origin. J Immunol 1963;91: 362-8
21. Hicks DJ, Fooks AR, Johnson N. Developments in rabies vaccines. Clin Exp Immunol 2012;169:199-204
22. Schwab MP, Fox JP, Conwell DP, Robinson TA. Avianized rabies virus vaccination in man. Bull World Health Organ 1954;10:823-35
23. Fox JP, Koprowski H, Conwell DP, et al. Study of antirabies immunization of man; observations with HEP Flury and other vaccines, with and without hyperimmune serum, in primary and recall immunizations. Bull World Health Organ 1957;17:869-904
24. Plotkin SA. Vaccine production in human diploid cell strains. Am J Epidemiol 1971;94:303-6
25. Wiktor TJ, Koprowski H. Successful immunization of primates with rabies vaccine prepared in human diploid cell strain WI-38. Proc Soc Exp Biol Med 1965;118:1069-73
26. Turner GS, Aoki FY, Nicholson KG, et al. Human diploid cell strain rabies vaccine. Rapid prophylactic immunisation of volunteers with small doses. Lancet 1976;1: 1379-81
27. Plotkin SA, Koprowski H. Rabies vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Saunders Elsevier; Philadelphia: 2008. p. 687-714
28. Garner WR, Jones DO, Pratt E. Problems associated with rabies preexposure prophylaxis. JAMA 1976;235:131-2
29. Barth R, Gruschkau H, Bijok U, et al. A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests. J Biol Stand 1984;12:29-46
30. Toovey S. Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience. Travel Med Infect Dis 2007;5:327-48
31. Vodopija I, Ljubicic M, Baklaic Z. Antibody response to PCEC rabies vaccine following abbreviated (3 dose) immunization schedules. In: Vodopija I, Nicholson KG, Smerdel S, Bijok U, editors. Improvements in rabies post-exposure treatment. Zagreb Institute of Public Health; Zagreb: 1985. p. 175-7
32. Vodopija I, Sureau P, Lafon M, et al. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 1986;4:245-8
33. Dreesen DW, Fishbein DB, Kemp DT, Brown J. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989;7:397-400
34. Briggs DJ, Dreesen DW, Nicolay U, et al. Purified chick embryo cell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons. Vaccine 2000;19: 1055-60
35. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis 2002;2:327-43
36. Magpantay R, Bermal N, Medina P, Quiambao B. Safety and immunogenicity of rabies pre and post exposure intradermal regimens using Abhayrab, a purified vero cell rabies vaccine (PVRV) produced in India in healthy volunteers: towards greater affordability of rabies prophylaxis. Asian Biomed 2010;4(1):61-7
37. Sampath G, Madhusudana S, Sudarshan M, et al. Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine. Vaccine 2010;28(24):4086-90
38. Doddabele H, Shampur N, Gadey S, et al. Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India. Human Vacc Immunother 2014;10(1):2796-801
39. Barth R, Franke V. Purified chick-embryo cell vaccine for humans. In: Meslin FX, Kaplan MM, Koprowski H, editors. Laboratory techniques in rabies. 4th edition. WHO; Geneva: 1996. p. 290-4
40. WHO prequalified vaccines. World Health Organization. Available from: www.who.int/immunization-standards/vaccine-quality/PQ-vaccine-list-en/en/index.html [Last accessed 25 March 2014]
41. Sampath G, Deshpande A, Briggs D, et al. Comparison of immunogenicity and safety of Purified Chick Embryo Culture Rabies Vaccine (PCECV) manufactured in India with PCECV manufactured in Germany. Proceedings of the XIII International Meeting on Research Advances and Rabies Control in the Americas. 2002
42. Zhu FC, Wu CH, Meng FY. [Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India (transl)]. Zhongguo Yi Miao He Mian Yi 2009;15:447-50
43. Finke S, Karger A, Freuling C, Müller T. Assessment of inactivated human rabies vaccines: biochemical characterization and genetic identification of virus strains. Vaccine 2012;30:3603-9
44. Briggs DJ; World Health Organization. The immunological basis for immunization series. Module 17: Rabies. Available from: http://whqlibdoc.who.int/publications/2011/9789241501088-eng.pdf [Last accessed 25 March 2014]
45. Rabies vaccines: world Health Organization position paper. Wkly Epidemiol Rec 2010;32:309-20
46. Centers for Disease Control and Prevention. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2010; 59(RR-2):1-9
47. World Health Organization expert committee on rabies. Eighth report. World Health Organ Tech Rep Ser 1992;824:1-84
48. Scheiermann N, Baer J, Hilfenhaus J, et al. Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC)-rabies vaccine in man. Zentralbl Bakteriol Mikrobiol Hyg A 1987;265: 439-50
49. Liu H, Huang G, Tang Q, et al. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin 2011;7:220-4
50. Vodopija I, Sureau P, Smerdel S, et al. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 1988;6:283-6
51. Beran J, Honegr K, Banzhoff A, Malerczyk C. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Vaccine 2005;23:3902-7
52. Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000;78: 693-8
53. Quiambao BP, Dimaano EM, Ambas C, et al. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005;23:1709-14
54. Suntharasamai P, Chaiprasithikul P, Wasi C, et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. Vaccine 1994;12:508-12
55. Wasi C, Chaiprasithikul P, Auewarakul P, et al. The abbreviated 2-1-1 schedule of purified chick embryo cell rabies vaccination for rabies postexposure treatment. Southeast Asian J Trop Med Public Health 1993;24: 461-6
56. Novartis Vaccines. Rabipur summary of product characteristics. 2010
57. Lumbiganon P, Chaiprasithikul P, Sookpranee T, et al. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. Asian Pac J Allergy Immunol 1989;7:99-101
58. Shanbag P, Shah N, Kulkarni M, et al. Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). Hum Vaccin 2008;4:365-9
59. Pengsaa K, Limkittikul K, Sabchareon A, et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12-to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr Infect Dis J 2009;28:335-7
60. Kamoltham T, Thinyounyong W, Phongchamnaphai P, et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 2007;151: 173-7
61. Kamoltham T, Thinyounyong W, Khawplod P, et al. Immunogenicity of simulated PCECV postexposure booster doses 1, 3, and 5 Years after 2-dose and 3-dose primary rabies vaccination in schoolchildren. Adv Prev Med 2011;2011:403201
62. Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009;4:e4708
63. Sampath G, Parikh S, Sangram P, Briggs DJ. Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals. Vaccine 2005;23:1102-5
64. Sehgal S, Bhattacharya D, Bhardwaj M. Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre-and post-exposure prophylaxis of rabies in Indian population. J Commun Dis 1995;27:36-43
65. Sehgal S, Bhardwaj M, Bhattacharya D. Immunogenicity and feasibility of purified chick embryo cell vaccine. Indian Pediatr 1994;31:133-7
66. Lumbiganon P and Wasi C. Survival after rabies immunisation in newborn infant of affected mother. Lancet 1990;336:319
67. Adeiga AA, Akinosho RO, Onyewuche J. Evaluation of immune response in infants with different nutritional status: vaccinated against tuberculosis, measles and poliomyelitis. J Trop Pediatr 1994;40: 345-50
68. Müller-Holve W, Leitritz H, Knorr E. [Early development of a child following rabies of the mother during pregnancy (author's transl)]. Infection 1977;5:49-50
69. Sipahioglu U, Alpaut S. [Transplacental rabies in humans (transl)]. Mikrobiyol Bul 1985;19:95-9
70. Sudarshan MK, Giri MS, Mahendra BJ, et al. Assessing the safety of post-exposure rabies immunization in pregnancy. Hum Vaccin 2007;3:87-9
71. Manning SE, Rupprecht CE, Fishbein D, et al. Human Rabies Prevention-United States 2008. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57(RR-3):1-28
72. Barbi M, Bardare M, Luraschi C, et al. Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers. Eur J Epidemiol 1992;8: 211-16
73. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994;8:469-76
74. Jaijaroensup W, Tantawichien T, Khawplod P, et al. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis 1999;28:913-14
75. Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis 2001; 33(10):e122-4
76. Thisyakorn T, Pancharoen C, Wilde H. Immunologic and virologic evaluation of HIV-infected children after rabies vaccination. Vaccine 2001;19(2001):1534-7
77. Gelinck L, Jol-van der Zijde C, Jansen-Hoogendijk A, et al. Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART. AIDS 2009;23:2451-8
78. Pancharoen C, Thisyakorn U, Tantawichien T, et al. Failure of pre-and postexposure rabies vaccinations in a child infected with HIV. Scand J Infect Dis 2001;33:390-1
79. Deshpande A, Briggs DJ, Banzhoff A. Investigation of immune response To purified chick embryo cell tissue culture rabies vaccine (PCECV) in HIV infected individuals using a simulated post-exposure regimen. Proceedings of the XIII International AIDS Conference; 2000. 163-8
80. Deshpande A, Briggs DJ. Rabies vaccination in immunosuppressed patients. In: Dodet B, Meslin FX, Heseltine E, editors. Rabies Control in Asia. Fourth International Symposium on Rabies Control in Asia John Libbey Eurotext; Montrouge: 2001. p. 58-60
81. Malerczyk C, Briggs DJ, Dreesen DW, Banzhoff A. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med 2007;14:63-4
82. Thraenhart O, Kreuzfelder E, Hillebrandt M, et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol 1994;71:287-92
83. Malerczyk C, Selhorst T, Tordo N, et al. Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains. Vaccine 2009;27:5320-5
84. Dobardzic A, Izurieta H, Woo EJ, et al. Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 2007;25:4244-51
85. Deshmukh DG, Damle AS, Bajaj JK, et al. Fatal rabies despite post-exposure prophylaxis. Indian J Med Microbiol 2011;29:178-80
86. Fescharek R, Schwarz S, Quast U, et al. Postexposure rabies prophylaxis: when the guidelines are not respected. Vaccine 1991;9:868-72
87. Madhusudana SN, Aggarwal P, Tripathi KK. Failure of rabies postexposure treatment with purified chick embryo cell (PCEC) vaccine. Vaccine 1989;7:478-9
88. Wilde H, Sirikawin S, Sabcharoen A, et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996;22:228-32
89. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007;25:7605-9
90. Shantavasinkul P, Tantawichien T, Wacharapluesadee S, et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin Infect Dis 2010;50:77-9
91. Wunner WH, Briggs DJ. Rabies in the 21 century. PLoS Negl Trop Dis 2010;4: e591
92. Bijok U, Barth R, Gruschkau H, et al. Clinical trials in healthy volunteers with the new purified chick embryo cell rabies vaccine for man. J Commun Dis 1984;16: 61-9
93. Bijok U, Vodopija I, Smerdel S. Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials. Behring Inst Mitt 1984;76:155-64
94. Bijok U. Purified chick embryo cell (PCEC) rabies vaccine-A review of the clinical development 1982-1984. In: Vodopija I, Nicholson KG, Smerdel S, Bijok U, editors. Improvements in Rabies Post-Exposure Treatment. Zagreb Institute of Public Health; Zagreb: 1985. p. 103-11
95. Barth R, Bijok U, Gruschkau H, et al. Purified chicken embryo cell rabies vaccine for human use. Lancet 1983;1:700
96. Wasi C, Chaiprasithikul P, Chavanich L, et al. Effective pre-and post-exposure treatment with purified chick embryo rabies vaccine. J Infect Dis Antimicrob Agents 1985;2:67-73
97. Wasi C, Chaiprasithikul P, Chavanich L, et al. Purified chick embryo cell rabies vaccine. Lancet 1986;1:40
98. Nicholson KG, Farrow PR, Bijok U, Barth R. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. Vaccine 1987;5: 208-10
99. Suntharasamai P, Warrell MJ, Viravan C, et al. Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis. Epidemiol Infect 1987;99:755-65
100. Madhusudana SN, Tripathi KK. Post exposure studies with human diploid cell rabies vaccine and purified chick embryo cell vaccine: comparative serological responses in man. Zentralbl Bakteriol 1989;271:345-50
101. Natarajan M, Mukundan P, John TJ. Immune response to purified chick embryo cell culture rabies vaccine manufactured in India. Indian J Med Res 1992;95:51-3
102. Kulkarni R, Thatte U, Shinde V, et al. A comparison of the tolerability of two dilution volumes (0.5 mL and 1.0 mL) of a purified chick embryo cell rabies vaccine administered intramuscularly to healthy adult volunteers: a randomized, intraindividual, assessor-blind study. Curr Ther Res 2004;65:47-56
103. Tanterdtham S, Chaiprasithikul P, Yuthavong K, Wasi C. Follow-up of protective antibody level after post-exposure vaccination with purified tissue culture rabies vaccine (PCEC) small doses intradermally. J Med Assoc Thai 1991;74: 498-501
104. Meesomboon V, Kingnate D, Samuthananont P. Antibody response to PCEC rabies vaccine following 0.1 ml immunization regimens. Com Dis J 1992;18:108-13
105. Charanasri U, Meesomboon V, Kingnate D, et al. Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. J Med Assoc Thai 1992;75:639-43
106. Madhusudana SN, Anand NP, Shamsundar R. Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals. Int J Infect Dis 2002;6:210-14
107. Madhusudana SN, Sanjay TV, Mahendra BJ, Suja MS. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen. Int J Infect Dis 2004;8:175-9
108. Chhabra M, Ichhpujani RL, Bhardwaj M, et al. Safety and immunogenicity of the intradermal Thai red cross (2-2-2-0-1-1) post exposure vaccination regimen in the Indian population using purified chick embryo cell rabies vaccine. Indian J Med Microbiol 2005;23:24-8
109. Sudarshan MK, Madhusudana SN, Mahendra BJ, et al. Evaluation of a new five-injection, two-site, intradermal schedule for purified chick embryo cell rabies vaccine: a randomized, open-label, active-controlled trial in healthy adult volunteers in India. Curr Ther Res 2005;66: 323-34
110. Ambrozaitis A, Laiskonis A, Balciuniene L, et al. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine 2006;24:4116-21
111. Madhusudana SN, Sanjay TV, Mahendra BJ, et al. Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML. Hum Vaccin 2006;2:200-4
112. Sudarshan MK, Narayana DH, Madhusudana SN, et al. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. Hum Vaccin Immunother 2012;8:1077-81
113. Sirikwin S, Likanonsakul S, Waradejwinyoo S, et al. Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus. Vaccine 2009;27: 4350-4
114. Vodopija R, Lafont M, Baklaic Z, et al. Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vaccine 1997;15:571-4
115. Ljubicic M, Vodopija I, Smerdel S, et al. Efficacy of PCEC vaccine in post-exposure rabies prophylaxis. In: Vodopija I, Nicholson KG, Smerdel S, Bijok U, editors. Improvements in rabies post-exposure treatment. Zagreb Institute of Public Health; Zagreb: 1985. p. 95-101
116. Tanphaichitra D, Siristonpun Y. Study of the efficacy of a purified chick embryo cell vaccine in patients bitten by rabid animals. Int Med 1987;3:158-60
117. Sehgal S, Bhardwaj M, Bhatia R Clinical evaluation of purified chick embryo cell antirabies vaccine for post-exposure treatment. J Commun Dis 1988;20:293-300
118. Vodopija I, Smerdel S, Bijok U. PCEC rabies vaccine and HRIG in post-exposure protection against rabies. In: Kuwert EK, Merieux C, Koprowski H, Bogel K, editors. Rabies in the Tropics. Springer; Berlin Heidelberg: 1985. p. 133-7
119. Kamoltham T, Singha J, Promsaranee U, et al. Elimination of human rabies in a canine endemic province in Thailand: five-year programme. Bull World Health Organ 2003;81:375-81